Q BioMed to Present at 2019 BIO CEO & Investor Conference

On February 1, 2019 Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, reported the Company’s CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at the BIO CEO & Investor Conference on February 11th -12th, 2019 in New York City (Press release, Q BioMed, FEB 1, 2019, View Source;investor-conference-300788230.html [SID1234533016]). The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Corin is scheduled to present at 3:00 PM on Monday, February 11th in the Chelsea room of the New York Marriott Marquis.

He will provide an update on the Company’s robust clinical pipeline including its FDA approved non-opioid drug Metastron, which relieves the severe pain associated with cancer that has metastasized to the bones. Metastron is expected to begin generating revenues for the Company in 2019.